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Abstract 
Evidence is emerging for an inverse association between statin use and cancer risk. Of all 
the cancers studied, data for prostate cancer are the most promising, particularly for advanced 
disease. Epidemiological evidence for such an association is supported by a number of pre-
clinical studies that show statins directly inhibit prostate cancer development and progression in 
cell-based and animal-based models. The antineoplastic effect of statins may be explained by a 
number of cholesterol-mediated and non-cholesterol-mediated mechanisms. Understanding these 
mechanisms is instrumental for future drug discovery efforts for the development of next 
generation prostate cancer therapeutics as well as for designing clinical trials for statins. In this 
review, we review possible antineoplastic mechanisms by which statins may exert their anti-
cancer effects. We also analyze the most recent human data regarding the association between 
statin use and prostate cancer risk. Finally, we discuss areas that, in our opinion, should receive 
top priority for future funding and research efforts. While currently there are insufficient data to 
advocate statin use for the primary prevention of prostate cancer, the motivation to move forward 
with further research is clear. 
  
Key points  
 Statins are a commonly-prescribed class of medications that effectively lower serum 
cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase, the rate-limiting enzyme for cholesterol synthesis in the liver. 
 Animal-based and cell-based preclinical models demonstrate that statins may inhibit prostate 
cancer growth through cholesterol-mediated (e.g. lipid raft-mediated signaling, de novo 
steroidogenesis) and non-cholesterol-mediated mechanisms (e.g. Ras signaling) that affect 
many pathways essential for cancer formation and progression. 
 More than 30 observational studies of statin use and prostate cancer risk have been 
completed to date, with the preponderance of evidence supporting a role for statins in 
reducing the risk of advanced prostate cancer. 
 Elevated rates of PSA screening and health-seeking behaviors in statin users may bias the 
findings of some epidemiologic studies, but are unlikely to fully explain the association 
between statin use and prostate cancer. Inverse associations between statin use and risk of 
advanced prostate cancer have been reported both by European and North American studies 
(populations with low and high PSA screening rates, respectively). 
 Statin use has also been associated with improved prostate cancer-specific survival, 
suggesting a potential role for statins in secondary and tertiary prostate cancer prevention. 
These epidemiologic findings are particularly pronounced in men undergoing radiation 
therapy, and laboratory studies support a role for statins in radio-sensitizing prostate tumor 
cells. 
 Prior to conducting primary prevention trials, there is a need for further basic research in 
order to understand the mechanisms contributing to inverse associations reported by 
observational studies. However, statin secondary and tertiary prevention trials with a goal to 
improve therapeutic outcomes for men already diagnosed with prostate cancer may be 
realized in the not too distant future. 
  
Introduction 
 Statins refer to a class of medications that effectively lower serum cholesterol levels by 
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting 
enzyme for cholesterol synthesis in the liver. In view of the epidemic nature of hyperlipidemia in 
the United States 1, statins are becoming one of the most commonly prescribed medications. In 
2012, more than one in four US adults over 40 years of age reported using statins, with 
simvastatin the most commonly used (42% of all statin users), followed by atorvastatin (20% of 
all statin users) 2. There is unequivocal evidence that statins reduce the number of adverse 
cardiovascular events associated with hyperlipidemia 3; more recently, however, evidence is 
growing for a potential role for statins in chemoprevention 4-11. Statins have been linked with 
reduced risk of several cancer types, with the most promising evidence supporting a role for 
statins in preventing prostate cancer, especially more advanced forms 6-11. However, as not all 
data agree on the potential benefits of statins, especially regarding the potential role of statins in 
reducing risk of total prostate cancer, it is still too early to advocate that all men start statins as a 
chemopreventative measure for prostate cancer 3, 12, 13.  
In this review, we will thoroughly present the most current evidence both for and against 
a potential role for statins in the chemoprevention of prostate cancer. We will review pre-clinical 
studies that examined the molecular mechanisms of how statins may inhibit prostate cancer 
growth using cell-based and animal-based models. We will then critically examine the most 
recent human data that studied associations between statins and prostate cancer, and special 
emphasis will be given to accumulating evidence that supports a role for statins in preventing 
advanced prostate cancer and prostate cancer progression. Finally, we will discuss the current 
gaps in our understanding of how statins may modify prostate cancer risk that must be filled in 
order to better guide future research and funding strategies.  
Statin medications: the basics 
 It is well established that statins reduce the number of adverse cardiovascular events 
associated with hyperlipidemia. This is achieved by lowering total serum cholesterol and low 
density lipoprotein (LDL) cholesterol levels secondary to inhibition of hepatic HMG-CoA 
reductase, an enzyme that catalyzes the rate-limiting step in hepatic cholesterol biosynthesis 3. 
Statins can be classified as either hydrophilic or lipophilic with respect to their solubility (Table 
1) 14. Hydrophilic statins are more hepatoselective given their active transport into the liver and 
their exclusion by other tissue types. As such, lipophilic statins have been hypothesized to have a 
greater influence on the prostate, although this has not been conclusively demonstrated by 
observational studies of statins and prostate cancer risk (Table 2) 6, 15-17. Statins are generally 
well tolerated with the most common side effects being hepatic dysfunction and muscle 
myopathies. A meta-analysis of 35 clinical trials of statin users vs. non-users concluded that 
statin therapy is only associated with a small excess risk of hepatic dysfunction but not of 
myalgias, rhabdomyolysis or creatine kinase elevations (a marker of myopathy) 18. Another 
meta-analysis of 13 clinical trials showed that statin use was associated with a slightly elevated 
risk of new-onset diabetes, although this risk was offset by the cardiovascular benefits of statins 
19.  
In view of the efficacy and safety of statins, it is not surprising to know that once the first 
statin, lovastatin, was approved by the United States Food and Drug Administration in 1987, six 
others joined lovastatin and collectively the market for statins has been growing ever since 
(Figure 1) 20, 21. Interestingly, the cardiovascular benefits of statin use have been observed in 
users that don’t have elevated cholesterol 22 suggesting that statins may have other actions in 
addition to cholesterol lowering. These findings regarding the “pleiotropic” effects of statins lend 
support to the rationale to examine whether statins may modify cancer risk.  
Understanding the basic science of statins and prostate cancer prevention 
 Considering the mounting evidence from human studies supporting a role for statins in 
modifying prostate cancer risk, it becomes essential to decipher potential mechanisms that could 
explain any benefits of statins at the molecular level using established animal-based and cell-
based preclinical models. As summarized in Figure 2, there is currently wealth of data from these 
models demonstrating that statins may inhibit prostate cancer growth through cholesterol-
mediated and non-cholesterol-mediated mechanisms that affect many pathways essential for 
cancer formation and progression. Specifically, using these models, statins have been shown to 
inhibit prostate cancer inflammation 23, angiogenesis 24, cell proliferation 25, migration/adhesion 
26, and invasion 27, and to promote apoptosis 28. Moreover, inhibition of HMG-CoA reductase by 
statins lowers the concentration of mevalonate and consequently the downstream isoprenylated 
intermediates believed to play an essential role in signaling pathways that support cancer 
formation and progression 29. 
Cholesterol-mediated pathways 
As early as 1981, Schaffner noted a positive correlation between cholesterol 
accumulation in prostatic tissues and the presence of prostate cancer 30. Several mechanisms 
have since been shown to contribute to dysregulation of cholesterol homeostasis in prostate 
cancer. One study found that hypermethylation of the cholesterol efflux transporter ABCA1 
resulted in reduced ABCA1 expression, lower cholesterol efflux rates and elevated levels of 
intracellular cholesterol in prostate cancer cell lines, and this epigenetic alteration was associated 
with high-grade prostate cancer in humans 31. Activation of the mTOR pathway plays an 
important role in regulating sterol responsive element binding proteins (SREBPs), transcription 
factors that control lipid and cholesterol homeostasis 32. Indeed, another study reported that 
intracellular accumulation of cholesteryl ester in lipid droplets was driven by loss of the tumor 
suppressor, PTEN, and subsequent activation of the PI3K/Akt/mTOR signaling pathway, and 
that intracellular accumulation of cholesterol ester was associated with high-grade prostate 
cancer in humans 33.  
One of the major cholesterol-mediated mechanisms through which statins inhibit tumour 
growth involves specialized cholesterol-rich regions of the membrane known as lipid rafts 34. 
These domains facilitate membrane-initiated signaling events in the cell through 
compartmentalization of signaling pathways, thereby enhancing tumour growth. Cell signaling 
pathways implicated in prostate cancer development and progression which may be mediated by 
cholesterol composition of lipid rafts include androgen receptor 35, epidermal growth factor 
receptor (EGFR) 36 and luteinizing hormone receptor 37 pathways. It is believed that statins, 
through their effect on intracellular cholesterol homeostasis, disrupt organization of these 
specialized domains and thus interfere with the above or other downstream intracellular signaling 
pathways 38.  
A direct example of the effect of reducing cholesterol content of the rafts on membrane-
initiated signaling is EGFR, a cell membrane-bound receptor recently found to associate with 
lipid rafts in prostate cancer cells 36. EGFR activation leads to Akt activation, a potent promoter 
of the growth of several solid tumour types, including prostate cancer 39. It has been shown that 
pharmacological treatment of prostate cancer cells with cholesterol binders disrupted lipid raft 
organization and interfered with EGFR signaling 36. Moreover, a recent study found that 
activation of cholesterol efflux in LNCaP cells and xenografts through pharmacological 
treatment with a Liver X Receptor (LXR) agonist induced apoptosis through disruption of lipid 
rafts and consequent downregulation of Akt signaling 40. Other signaling pathways implicated in 
prostate cancer and development of castration resistance such as interleukin-6 activation or 
signal transducer and activator of transcription-3 (STAT-3) have similarly been found to be 
associated with lipid raft organization and thus are under the potential influence of lipid raft 
cholesterol concentrations 41. The importance of cholesterol has also been seen in a mouse 
model. Mice were fed a high-fat, high-cholesterol diet and injected with LNCaP subcutaneous 
xenografts and were compared to mice consuming a low-fat, low-cholesterol diet. Elevated 
cholesterol in the serum of high-fat fed mice promoted tumour growth and reduced apoptosis, in 
part by increasing activity of Akt. Interestingly, inhibition of cholesterol synthesis with a statin 
disrupted lipid rafts in the tumours and induced apoptosis through attenuation of Akt signaling 42.  
 Alternatively, with cholesterol being a precursor for androgens, lowering cholesterol 
levels using statins may reduce prostate cancer growth by reducing serum or intra-tumoural 
levels of androgens. The effect of statins on serum androgen levels of is unclear. While some 
studies have suggested statins reduce serum testosterone levels 43-45, these reductions are small or 
associated with higher statin doses than used in common clinical practice. Other observational 
studies 46, 47, and two clinical trials 48, 49 found no association between statin use and serum 
androgen levels. Most recently, a nested study of 1,812 men in the Boston Area Community 
Health Survey cohort, of which 237 (12.4%) were statin users, found no association between 
statin use and serum androgen levels 50. 
Emerging evidence suggests that even when castrate levels of androgens are achieved in 
the serum of prostate cancer patients, intra-prostatic levels of androgen remain high possibly due 
to de novo androgen synthesis 51-53. Thus, it remains conceivable that statins, by lowering intra-
prostatic cholesterol levels, could lower intra-prostatic androgen levels. Indeed, a recent study 
found that hypercholesterolemia induced in non-castrated mice by a high fat, high cholesterol 
diet increased the intra-tumoural levels of androgens in LNCaP xenografts without having an 
effect on serum androgens, suggesting that hypercholesterolemia induces intra-tumoural de novo 
steroidogenesis 54. 
Non-cholesterol-mediated pathways 
 Statins inhibit the conversion of HMG-CoA to mevalonate thereby reducing mevalonate 
cellular concentrations. Mevalonate is a precursor for a class of compounds called isoprenoids, 
such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GPP). FPP and GPP 
facilitate the recruitment of signaling proteins such as the Ras/Rho family of G-proteins by 
bridging their attachment to the plasma membranes where their signaling activities can promote 
prostate cancer cell survival and proliferation 55, 56. Thus, statins, by reducing mevalonate and 
downstream isoprenoids may inhibit cancer cell proliferation. 
Furthermore, statins appear to directly induce apoptosis in cancer cells independent of 
their effect on cholesterol. This has been reviewed elsewhere 29, but with respect to prostate 
cancer statins can, for example, inhibit cyclin-dependent kinase-2 and stimulate cell-cycle arrest 
57, or even activate specific proteases that themselves can later activate apoptosis 58. Statins also 
have direct anti-inflammatory and anti-angiogenic properties which conceivably may also inhibit 
cancer growth and progression 29. A recent study in a cohort of men undergoing radical 
prostatectomy at a VA medical center found that statin users have significantly lower levels of 
prostate inflammation within their prostate tumours than non-users 59. 
Evidence from epidemiologic studies: statins and prostate cancer prevention  
In the last few years there has been increasing interest in the use of statins for prostate 
cancer prevention 60. It has even been suggested that statins may be partially responsible for the 
steep decline in the prostate cancer mortality rate witnessed over the last 15 years 61 as it 
paralleled the introduction and distribution of statins (Figure 1). Upon closer inspection of 
epidemiologic studies and secondary analyses of randomized controlled trials, it appears that the 
preponderance of evidence supports a role for statins in reducing prostate cancer risk with the 
strongest evidence to date supporting that statins may selectively lower the risk of advanced 
prostate cancer. As outlined in this section, in addition to data supporting an inverse association 
between statin use and risk of advanced prostate cancer, there is also evidence that statins may 
impact prostate cancer progression at multiple stages of the disease course including biochemical 
recurrence after primary therapy, development of castrate resistance following androgen 
deprivation therapy, and prostate cancer-specific mortality (Figure 3).  
Total prostate cancer  
More than 30 observational studies (summarized in Table 2) have examined the link 
between statin use and total prostate cancer risk with encouraging, though conflicting results. A 
number of case-control studies reported null associations 7, 15, 62-64, but three reported an elevated 
risk of total prostate cancer in statin users 10, 65, 66. However, one of these studies suggested that 
the positive association between statin use and total prostate cancer risk is potentially attributable 
to bias arising from increased surveillance in men initiating statin treatment 10. Indeed, the 
Finnish study found that the elevated prostate cancer risk in new statin users disappeared with 
increasing duration of statin use, supporting this possible explanation 66. The largest population-
based case-control study to date, a Danish study that included more than 40,000 total prostate 
cancer cases and over 200,000 controls, reported a significant 6% reduced risk of total prostate 
cancer in statin users 17.  
A cohort study of >55,000 men in the Veterans Administration (VA) Health System 
found statin users were 31% less likely to be diagnosed with total prostate cancer 67. Two cohort 
studies examining men undergoing PSA screening found a 25% 68 and 64% 69 reduced prostate 
cancer risk in statin users, while a cohort study examining men undergoing prostate biopsy 
reported a 8% reduced risk of total prostate cancer in statin users 70. A retrospective cohort in 
Israel found a 74% reduced risk of total prostate cancer in long-term statin users, defined as at 
least 5 years of statin use, relative to non-users 71. Other studies found weaker, but still inverse 
associations between statin use and total prostate cancer risk 72, 73, including a population-based 
study in Washington State that found statin users had a 12% lower prostate cancer risk (HR 0.88, 
95% CI, 0.76-1.02), though this did not reach significance 16. Despite these promising data, other 
studies found no link between statin use and total prostate cancer risk, including a secondary 
analysis of a randomized trial of men with a negative prostate biopsy who underwent repeat 
biopsies at two and four years 74, in addition to several observational studies 5, 11, 75-78. Despite 
conflicting findings from individual case-control and cohort studies, the most recent meta-
analysis of these studies reported a 7% significantly reduced risk of total prostate cancer in statin 
users 79.  
Multiple meta-analyses of randomized controlled trials of statin use in the primary and 
secondary prevention of adverse cardiovascular outcomes reported null associations between 
statin use and total prostate cancer risk 80-82. It is widely acknowledged that trial participants may 
not be representative of the general population. For example, all statin trials incorporated dietary 
interventions in both statin and placebo groups and all trial participants had a history of 
cardiovascular disease 3. Furthermore, while the most commonly-used statin in the United States 
is simvastatin (Table 1) 2, the majority of clinical trials randomized participants to pravastatin, a 
weaker inhibitor of HMG-CoA reductase with reduced cholesterol-lowering efficacy 83. Finally, 
randomized controlled trials have relatively short follow-up periods, with a median of 4.8 years 
of follow up across the 27 statin trials to date 80. Together, these factors could explain differences 
in associations between statin use and total prostate cancer risk reported by observational studies 
and randomized trials.  
Advanced prostate cancer 
 While the data examining associations between statins and total prostate cancer are 
unclear, there are increasing data indicating that statins may selectively lower the risk of 
advanced prostate cancer, with advanced prostate cancer defined using Gleason grade, clinical 
stage or a combination of both variables (Table 2). Indeed, five large prospective studies all 
found that statin users had reduced risk of advanced prostate cancer without any reduction or 
with a greatly attenuated reduction in total prostate cancer risk 8, 9, 11, 67, 84.  
The Health Professionals Follow-up Study followed 34,989 men who were cancer free in 
1990 until 2002 8. In this study, statin use was associated with a 49% reduced risk of advanced 
prostate cancer and a 61% reduced risk of metastatic or fatal prostate cancer. Interestingly, statin 
use was not associated with risk of total prostate cancer. Moreover, among men with ≥5 years of 
statin use, the risk of advanced prostate cancer was reduced by 74%. 
 The Cancer Prevention Study II Nutrition Cohort (n=55,454) 9, the California Men’s 
Health Cohort Study (n=69,047) 11, and a case-control study set in the Finnish population 
(n=24,723) 10, observed 40%, 20% and 25% reductions respectively in the risk of advanced 
prostate cancer among longer-term (≥5years 9, 11 or ≥915 defined daily doses 10) statin users. 
Although the risk reduction observed in the California Men’s Health Cohort did not reach 
statistical significance, the study findings are still encouraging considering the low number of 
men diagnosed with advanced prostate cancer (n=131). The introduction of bias was minimized 
in all four studies by controlling for potential confounding variables including use of other 
medications, diabetes, diabetes treatments and other cardiovascular risk factors that are 
associated with prostate cancer such as age, race and body mass index.  
More recently, in 2012, a meta-analysis of 27 observational studies found that statin use 
was associated with only a modest reduction in total prostate cancer risk (7%) but a more 
pronounced reduction in advanced disease risk (20%) 79. Since then, four additional studies 
reported an inverse association between statin use and lethal prostate cancer; a case only analysis 
of 1,001 prostate cancer patients of whom 289 were statin users reported a hazard ratio (HR) of 
0.19 (95% CI: 0.06, 0.56) of prostate cancer-specific mortality for statin users versus non-users 
85. A registry-based study in a Danish population where statin use began before cancer diagnosis 
found that statin users had significantly lower prostate cancer-specific mortality, and this finding 
was also observed for 12 other cancer types 86. A study originally designed to assess the 
association between beta blockers and prostate cancer-specific mortality found that statin use 
was inversely associated with lethal prostate cancer among 3,561 men 87. Finally, a study 
conducted in a large, population-based electronic database in the United Kingdom found that use 
of statins was even more strongly associated with a lower risk of lethal disease if started before 
diagnosis 88.  
PSA testing is the most widely-used method for prostate cancer screening. The 
implication of this is if statin use affects PSA levels, bias would potentially be introduced in all 
of the above observational studies. Indeed, a pilot study of 15 statin users demonstrated that 
statin use caused a 42% decline in PSA levels over a period of five years 89. To investigate how 
statin use affected PSA levels at the time of prostate cancer screening, we conducted a cross 
sectional study of 323,426 men aged ≥65 years who had a screening PSA test in 2003 at a VA 
facility. We found that statin use was associated with a lower probability that an older man will 
have an abnormal screening PSA result, regardless of the PSA threshold 90. Another study 
examined the effect of statin, thiazide diuretics and nonsteroidal anti-inflammatory drugs 
(NSAIDs) on PSA levels in a cohort of 1,864 men that had no history of prostate cancer, 
prostatitis, or recent prostate manipulations in the National Health and Nutrition Examination 
Survey (NHANES), found that statin use was inversely related to PSA levels (p=0.01) 91. Given 
the observation that statin use is associated with lower PSA levels at screening, one could 
imagine that lower PSA levels in statin users would trigger fewer biopsies and thus use of statins 
would be associated with a decreased incidence of total prostate cancer risk. However, as 
prostate cancer diagnosis would be delayed in this case, there would be an increased incidence of 
advanced prostate cancer among statin users. Based on the above discussion, it is unlikely that 
the effect of statins on PSA levels introduced any significant bias in the findings of the above 
studies because the exact opposite findings were observed in the vast majority (i.e. reduced risk 
of advanced disease). 
One could also argue that statin users may be more health conscious with more frequent 
visits to the health care system than non-users. This may make statin users more likely to be 
diagnosed with prostate cancer at an earlier stage of the disease than non-users. Early detection 
of prostate cancer and subsequent early treatment is associated with less frequent progression to 
advanced stages of the disease and may explain lower risk of advanced prostate cancer observed 
in statin users. However, a number of studies reported that adjusting for the intensity of PSA 
screening did not impact the association between statin use and risk of advanced disease 73, 92, 93. 
The most recent meta analysis reported that the findings of studies adjusting for PSA screening 
did not greatly differ from the findings of studies that did not adjust for PSA screening 79. 
Meanwhile, considering that the prevalence of PSA testing in Europe is exceedingly lower than 
in the United States, this makes the case-control studies set in Denmark and Finland relatively 
free from this potential bias 94. Yet, these studies also observed a significant reduction in the risk 
of advanced prostate cancer as did studies in the United States. 
Can statins in combination with prostate cancer therapies improve prostate cancer 
outcomes? 
 In addition to statins’ role as a potential agent for prostate cancer chemoprevention, 
investigators are beginning to study whether statins may improve the outcome of well-
established prostate cancer therapies. In a study of 938 men treated with brachytherapy, Moyad 
et al. compared outcomes of men taking statins (n=191) to non-statin users81. Statin users had 
smaller prostate volumes, lower PSA values and lower tumour volume in the biopsy specimens. 
There was a suggestion that statin use was associated with improved prostate cancer-specific and 
overall survival, although this association did not reach statistical significance. In a different 
study of 871 men with stage T1 to T3 prostate cancer treated with radiotherapy, 168 were taking 
a statin at the time of diagnosis82. In this study, use of statins was a significant predictor of 
improved PSA-free survival compared to non-users (p=0.03)82. Oh et al. retrospectively 
examined the association between use of statins and risk of biochemical recurrence in prostate 
cancer patients treated with permanent Iodine-125 brachytherapy at Durham VA Medical Center. 
In this study, statin use was associated with a significant delay in biochemical recurrence, 
relative to non-users83. Furthermore, a meta-analysis of 13 studies that examined the effect of 
statin use on biochemical recurrence following local treatment with radical prostatectomy or 
radiotherapy found that statins were associated with a statistically significant improvement in 
recurrence-free survival in patients who underwent radiotherapy (HR 0.68; 95% CI 0.49-0.93), 
but not in patients who underwent radical prostatectomy (HR 1.05; 95% CI 0.90-1.24) 95. Taken 
together, these results suggest statins may slow progression of prostate cancer in men undergoing 
radiation, possibly by sensitizing the cells to radiotherapy, though further study is needed to 
confirm these findings. It has been suggested that statin may radio-sensitize prostate tumor cells 
by causing growth arrest in the late G1, the phase of the cell cycle when cells are most sensitive 
to radiation-induced cell death 96. However, some evidence suggests that this association may not 
be limited to radiotherapy patients. A retrospective study that investigated the effect of statin use 
after radical prostatectomy on PSA recurrence in a cohort of men that never received statins 
before surgery found that use of statins was associated with a 36% reduction in the risk of PSA 
recurrence 97. Indeed, a study that examined the association of pre and postoperative use of 
statins in 2,137 Korean men who underwent radical prostatectomy between 1998 and 2011 at 
Asan Medical Center found that although preoperative use of statins was not associated with 
different pathologic outcome, postoperative use of statins enhanced recurrence-free survival 
especially in patients with high risk disease86. Finally, one study reported that statin use 
significantly prolonged time to progression in 926 men receiving androgen deprivation therapy 
(ADT), even after adjusting for known prognostic factors such as biopsy Gleason score, type of 
primary therapy, and presence of metastases at ADT initiation 98.     
 Statins have also been evaluated for their ability to reduce common side effects 
associated with local treatment of prostate cancer. For example, one important side effect is 
erectile dysfunction. Hong et al., in a randomized controlled trial, prospectively examined the 
effect of statins on recovery of erectile function after radical retropubic prostatectomy in 50 men 
without hypercholesterolemia who never used statins. The study found that postoperative 
treatment with a statin was associated with earlier recovery of erectile function as judged by a 
significantly improved Index of Erectile Function-5 score (p=0.003) in statin users vs. non-
users87. This result is in agreement with a recent meta-analysis of 11 prospective randomized 
clinical trials which found that randomization to statins resulted in a clinically relevant 
improvement in erectile function even after adjusting for the average age of participants and 
level of LDL cholesterol, two potential confounding factors88.  
Moving forward 
 Successful completion of the Prostate Cancer Prevention Trial (PCPT), the Reduction by 
Dutasteride of Prostate Cancer Events (REDUCE), and the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT) demonstrates that participants can be recruited for large prostate 
cancer primary prevention trials. Considering mounting evidence that supports a role for statins 
in reducing prostate cancer risk, especially advanced prostate cancer, do we launch a similar size 
trial to test the efficacy of statins in the primary prevention of prostate cancer? We strongly 
believe the short answer is “NOT YET” due to the following reasons. First, from a basic science 
perspective, our understanding of the many potential mechanisms through which statins may 
prevent development and progression of cancer is still far from complete. Deciphering these 
mechanisms will allow us to identify novel anti-cancer pathways that could inform the 
development of next generation prostate cancer therapeutics as well as help guide appropriate 
statin clinical trials with intermediate end-points. In addition, understanding the mechanisms 
linking cholesterol and prostate cancer will lead to the identification of tumor biomarkers 
indicating response to statins, thus enabling statin therapy to be targeted to patients predicted to 
show a tumor response. Second, it is unclear which type of statin would be most appropriate for 
use in a clinical trial. However, simvastatin is the most commonly-used statin in the vast 
majority of epidemiologic studies reporting an inverse association between statin use and risk of 
advanced prostate cancer, potentially supporting the use of simvastatin in prostate cancer trials. 
Future epidemiologic studies with sufficient sample size should interrogate the effects of 
different statin types on prostate cancer risk and progression or, at very least, report the 
frequency of use of different types of statin in their populations. Finally, two major obstacles to a 
primary prevention statin trial are readily foreseeable. First, as the prevalence of statin use is so 
great, it would be a considerable challenge to find eligible non-users who would enroll in such a 
trial and who would stay in the placebo arm without becoming statin users in later stages. 
Second, advanced prostate cancer is a relatively rare occurrence at the time of diagnosis in the 
PSA era. Since statins appear to be most strongly linked with reduced risk of this form of the 
disease, the number of men that would need to be randomized and the duration of their follow-up 
required to detect a difference in advanced disease would be vast. 
 Meanwhile, we feel that much can be learned without the need to launch such an 
expensive, large and time-consuming primary prevention trial. For example, there is a strong 
impetus to begin analyzing statins’ role in secondary and tertiary prevention; do statins improve 
outcomes in men already diagnosed with prostate cancer? While statins do not appear to impact 
risk of localized prostate cancer, epidemiologic evidence supports a role for statins in delaying 
disease recurrence and reducing prostate cancer-specific mortality regardless of disease 
characteristics at diagnosis, thereby providing rationale for secondary prevention trials among all 
prostate cancer patients. Late stage castrate resistant or metastatic prostate cancer is a disease of 
short duration and outcome events occur in the order of months to a couple of years. 
Accordingly, from an epidemiology standpoint, more meaningful results with much smaller 
sample sizes and shorter trial durations can be extrapolated from studying the role of statins in 
this disease stage. Much could be learned about the biology of statins here. Moving earlier in the 
spectrum of the disease to study men undergoing primary treatment would also yield information 
about how statins interact with our current treatment modalities and may identify factors that 
predict response, such as changes in lipid profiles following the start of statins. In men on active 
surveillance protocols, particularly among those at highest risk of disease progression, statins 
could be tested as an adjuvant therapy to reduce or delay the need for subsequent treatment and 
tumour response could be monitored in real-time using tumour imaging 99 Indeed, targeting high-
risk populations has been suggested as a way to maximize risk-benefit ratio by a recent 
commentary 100, although statins are well-tolerated drugs with few major side effects. Next 
generation prostate cancer drugs could be used separately or in combination with statins to 
reduce prostate cancer mortality and/or morbidity. Clinical trials to interrogate statins in 
combination with other agents are warranted, particularly those that show synergy in animal 
models and whose mechanism of synergistic activity is known. Indeed, a recent study that 
examined the effect of statins and metformin combinations on biochemical recurrence among 
diabetic men undergoing radical prostatectomy found that although neither statin nor metformin 
use alone was associated with reduced risk of biochemical recurrence, their interaction led to a 
significantly lower risk92. Other potential candidates for combination treatments are LXR 
agonists; these agents stimulate cholesterol efflux from cancer cells thus reducing their 
intracellular cholesterol stores and inducing apoptosis 40 and thereby may act synergistically with 
statins to inhibit prostate cancer growth. 
Conclusions 
 Mounting evidence is emerging from the current literature to support that statin use may 
be associated with a lower risk of advanced prostate cancer. While it is difficult to determine 
causality from observational studies, these epidemiological data are also supported by a plethora 
of preclinical studies showing that statins directly inhibit prostate cancer development and 
progression in cell-based and animal-based models. Thus, there is ample justification to proceed 
with further population-based and basic research, and the results from these studies will bolster 
current rationale for a primary prevention trial as well as targeted clinical trials with mechanistic 
end-points. At present, we still need more data regarding the “benefits” of statins before we can 
advocate that all men at risk of prostate cancer start statins regardless of their cholesterol profile. 
However, the use of statins in secondary and tertiary prevention to improve therapeutic outcomes 
for men already diagnosed with prostate cancer may be realized in the not too distant future.   
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Figure legends 
Figure 1: US prostate cancer-specific mortality rate 101, prevalence of high cholesterol in US 
males over 20 years of age 20, prevalence of statin use in US males over 40 years of age 2, and 
year of Federal Drug Administration (FDA) approval in the US for each type of statin. 
Figure 2: Cholesterol-mediated and non-cholesterol-mediated mechanisms contributing to the 
association between statin use and prostate cancer. 
Figure 3: Natural history of prostate cancer, with arrows indicating the stages of prostate cancer 
at which observational studies have demonstrated statins may play a protective role; 1) clinical 
manifestation of advanced prostate cancer, 2) biochemical recurrence after primary therapy, and 
3) development of castrate resistance (CRPC) after androgen deprivation therapy, leading to 4) 
prostate cancer death. 
Table 1: Pharmacologic characteristics of statin medications 2, 102, 103 
 
Statin type Frequency of 
use (%) in US 
statin users, 
2011-12 
Solubility IC
50 
(nM) for HMG-
CoA reductase 
inhibition 
Systemic 
bioavailability 
(%) 
Simvastatin 42.0 Lipophilic 11.2 <5 
Atorvastatin 20.2 Lipophilic 8.2 ~14 
Pravastatin 11.2 Hydrophilic 44.1 17 
Rosuvastatin 8.2 Hydrophilic 5.4 ~20 
Lovastatin 7.4 Lipophilic 2.7-11.1 <5 
Pitavastatin NR Lipophilic 6.8 >60 
Fluvastatin NR Lipophilic 27.6 24 
HMG-CoA reductase=3-hydroxy-3-methylglutaryl coenzyme A reductase; IC50=half maximal 
inhibitory concentration; NR=not reported 
Table 2: Observational studies of statin use and prostate cancer risk  
Study Design Country 
Number of 
subjects 
Statin type 
Follow 
up*  
Exposure 
definition for 
primary 
analysis 
Fully adjusted results for total and 
advanced prostate cancer 
Blais et 
al., 2000 
Population-
based nested 
case-control  
Canada  
780 controls; 
78 cases 
NR 
Median 
2.7 
years 
Statin use vs. 
use of bile 
acid-binding 
resins 
Total: RR 0.74 (95% CI 0.36-1.51) 
 
Graaf et 
al., 2004 
Population-
based nested 
case-control  
Nether-
lands 
16,976 
controls; 186 
cases 
80% 
simvastatin
; 7% 
pravastatin 
Mean 
7.2 
years 
Statin use vs. 
nonuse 
Total: OR 0.37 (95% CI 0.11-1.25) 
Kaye et 
al., 2004 
Case-control UK 
7,451 
controls; 569 
cases 
NR - 
Current statin 
use vs. nonuse 
(in men 
without hyper-
lipidemia) 
Total: RR 1.3 (95% CI 1.0-1.9) 
Friis et 
al., 2005 
Population-
based cohort  
Denmark 
168,133 men; 
1,626 cases 
Majority 
simvastatin 
Mean 4 
years 
Statin use vs. 
nonuse 
Total: RR 0.87 (95% CI 0.61-1.23) 
Shannon 
et al., 
2005 
Hospital-
based case 
control  
US 
202 controls; 
100 cases (57 
advanced) 
>97% 
simvastatin 
or 
lovastatin 
- 
Statin use vs. 
nonuse 
Total: OR 0.35 (95% CI 0.20-0.64) 
 
Advanceda: OR 0.24 (95% CI 0.11-0.53) 
Platz et 
al., 2006 
Prospective 
cohort  
US 
34,989 men; 
2,579 cases 
(316 
advanced) 
NR 
376,939 
person-
years  
Current statin 
use vs. 
never/past 
statin use 
Total: RR 0.96 (95% CI 0.85-1.09) 
 
Advancedb: RR 0.51 (95% CI 0.30-0.86) 
Flick et 
al., 
 2007 
Prospective 
cohort  
US 
69,047 men; 
888 cases 
(131 
advanced) 
64% 
lovastatin; 
30% 
simvastatin 
Median 
2.3 
years 
Statin use vs. 
nonuse 
Total: RR 0.92 (95% CI 0.79-1.07) 
 
Advancedc: RR 0.80 (95% CI 0.53-1.19) 
Jacobs et 
al., 2007 
Prospective 
cohort  
US 
55,454 men; 
3,413 cases 
(317 
advanced) 
NR NR 
Long-term 
statin use (≥5 
years) vs. 
nonuse 
Total: RR 1.06 (95% CI 0.93-1.20) 
 
Advancedd: RR 0.60 (95% CI 0.36-1.00) 
Murtola et 
al., 2007 
Population-
based case 
control 
Finland 
24,723 case 
control pairs 
(~3,700 
advanced) 
~50% 
simvastatin
, ~25% 
atorvastatin
, ~20% 
fluvastatin, 
~20% 
lovastatin 
- 
Statin use vs. 
nonuse 
Total: OR 1.07 (95% CI 1.00-1.16) 
 
Advancede: OR 0.75 (95% CI 0.62-0.91) 
Agalliu et 
al., 2008 
Population-
based case-
control 
US  
942 controls; 
1,001 cases 
(181 
advanced) 
~20% 
atorvastatin
, ~9% 
simvastatin 
- 
Statin use vs. 
nonuse 
Total: OR 0.98 (95% CI 0.80-1.21) 
 
Advancede: OR 0.79 (95% CI 0.53-1.17) 
Boudreau 
et al., 
2008 
Retrospectiv
e cohort 
US 
83,372 men; 
2,532 cases 
(740 
advanced) 
Majority 
lovastatin 
and 
simvastatin 
Median 
5.7 
years 
Statin use vs. 
nonuse 
Total: HR 0.88 (95% CI 0.76-1.02) 
 
Advancedf: HR 1.05 (95% CI 0.80-1.38) 
Friedman 
et al., 
2008 
Prospective 
cohort 
US 
2,097,474 
men; 1,706 
cases (217 
advanced) 
66% 
lovastatin, 
29% 
simvastatin 
Median 
4.9 
years 
Statin use vs. 
nonuse 
Total: HR 1.03 (95% CI 0.98-1.08) 
 
Advancedc: HR 0.83 (95% CI 0.72-0.96) 
Smeeth et 
al., 2009 
Prospective 
cohort  
UK 
364,675 men; 
3,525 cases 
>50% 
simvastatin 
or 
atorvastatin  
Median 
4.4 
years 
Statin use vs. 
nonuse 
Total: HR 1.06 (95% CI 0.86-1.30) 
Breau et 
al., 2010 
Prospective 
cohort 
US 
2,447 men; 
224 cases (56 
advanced) 
NR 
Median 
15 years 
Daily statin use 
vs. nonuse 
Total: HR 0.36 (95% CI 0.25-0.53) 
 
Advanceda: HR 0.25 (95% CI 0.11-0.58) 
Coogan et 
al., 2010 
Hospital-
based case 
control 
US 
2,007 
controls; 
1,367 cases 
Majority 
lipophilic  
- 
Statin use vs. 
nonuse 
Total: OR 1.1 (95% CI 0.9-1.5) 
 
Advancedg: OR 1.1 (95% CI 0.7-1.8) 
(# advanced 
NR) 
Haukka et 
al., 2010 
Population-
based nested 
case control 
Finland 
235,830 
statin 
user/non-user 
pairs (# cases 
NR) 
53% 
simvastatin
, 39% 
atorvastatin 
Mean 
8.8 
years 
Statin use vs. 
nonuse 
Total: RR 1.12 (95% CI 1.08-1.17) 
Hippisley-
Cox et al., 
2010 
Prospective 
cohort 
UK 
990,495 men; 
7,129 cases 
71% 
simvastatin
, 22% 
atorvastatin 
NR 
Statin use vs. 
nonuse  
Total: HR 1.05 (95% CI 0.98-1.13) 
Murtola et 
al., 2010 
Prospective 
cohort  
Finland  
23,320 men; 
1,594 cases 
(133 
advanced) 
45% 
simvastatin
, 41% 
atorvastatin 
Median 
6.9 
years 
Statin use vs. 
nonuse 
Total: HR 0.75 (95% CI 0.63-0.89) 
 
Advancedh: HR 0.93 (95% CI 0.54-1.58) 
Chang et 
al., 2011 
Population-
based case 
control 
Taiwan 
1,552 
controls; 388 
cases 
NR - 
Statin use vs. 
nonuse 
Total: OR 1.55 (95% CI 1.09-2.19) 
Farwell et 
al., 2011 
Retrospectiv
e cohort 
US 
55,875 men; 
546 cases 
(130 
advanced) 
55% 
simvastatin
, 44% 
lovastatin 
Median 
5.6 
years 
Statin use vs. 
hypertensive 
medication use 
Total: HR 0.69 (95% CI 0.52-0.90) 
 
Advancedi: HR 0.40 (95% CI 0.24-0.65) 
Fowke et 
al., 2011 
Cross 
sectional 
case control 
US 
1,304 
controls; 844 
cases (404 
advanced) 
40% 
simvastatin
, 35% 
atorvastatin
, 10% 
lovastatin 
- 
Current statin 
use vs. nonuse  
Advanceda: OR 0.95 (95% CI 0.73-1.24) 
Jacobs et 
al., 2011 
Prospective 
cohort  
US 
60,059 men; 
3,089 cases 
(324 
advanced) 
NR NR 
Long-term 
statin use (≥5 
years) vs. 
nonuse 
Total: RR 1.02 (95% CI 0.93-1.12) 
 
Advancedd: RR 0.86 (95% CI 0.62-1.18) 
Tan et al., 
2011 
Case-control US 
1,797 
controls; 
2,407 cases 
(1,681 
advanced) 
NR - 
Current statin 
use vs. nonuse 
Total: RR 0.92 (95% CI 0.85-0.98) 
 
Advanceda: RR 0.76 (95% CI 0.67-0.85) 
Chan et 
al., 2012 
Prospective 
cohort 
US 
5,069 men; 
356 cases 
(195 
advanced) 
NR 
Mean 7 
years 
Current statin 
use at baseline 
vs. nonuse  
Total: OR 1.07 (95% CI 0.82-1.40) 
 
Advanceda: OR 1.04 (95% CI 0.73-1.50) 
Freedland 
et al., 
2013 
Secondary 
analysis of 
prospective 
trial 
Multi-
national 
6,729 men, 
1,517 cases 
(456 
advanced) 
NR 
Prostate 
biopsy 
at 2 & 4 
years 
Statin use at 
baseline vs. 
nonuse 
Total: OR 1.05 (95% CI 0.89-1.24) 
 
Advanceda: OR 1.11 (0.85-1.45) 
Jespersen 
et al., 
2014 
Population-
based case-
control 
Denmark 
212,400 
controls; 
42,480 cases 
(12,412 
advanced) 
72% 
simvastatin
, 11% 
atorvastatin 
- 
Current statin 
use vs. nonuse 
Total: OR 0.94 (95% CI 0.91-0.97) 
 
Advancedh: OR 0.90 (95% CI 0.85-0.96) 
Lustman 
et al., 
2014 
Retrospectiv
e population-
based cohort 
Israel 
66,741 men; 
1,813 cases 
NR NR 
Long-term 
statin use (≥5 
years) vs. 
nonuse 
Total: HR 0.26 (95% CI 0.22-0.31) 
Morote et 
al., 2014 
Retrospectiv
e cohort 
Spain 
2,408 men; 
848 cases 
(240 
advanced) 
NR NR 
Long-term 
statin use (≥3 
years) vs. 
nonuse 
Total: OR 0.88 (95% CI 0.73-1.06) 
 
Advancedj: OR 1.15 (95% CI 0.82-1.63) 
Platz et 
al., 2014 
Prospective 
cohort  
US 
9,457 men 
and 574 
cases (156 
advanced) 
NR 7 years 
Statin use vs. 
nonuse 
Total: HR 1.03 (95% CI 0.82-1.30) 
 
Advanceda: HR 1.27 (95% CI 0.85-1.90) 
Kantor et 
al., 2015 
Prospective 
cohort  
US 
32,091 men; 
570 cases 
(107 
advanced) 
NR 
Mean 
5.2 
years 
Current statin 
use at baseline 
vs. nonuse 
Total: HR 0.86 (95% CI 0.63-1.18) 
 
Advancedi: HR 0.62 (95% CI 0.30-1.28) 
Nordstro
m et al., 
2015 
Retrospectiv
e cohort  
Sweden 
18,574 men; 
8,430 cases 
(4,242 
advanced) 
NR NR 
Statin use vs. 
nonuse 
Total: OR 1.16 (95% CI 1.04-1.29) 
 
Advanceda: OR 1.25 (95% CI 1.10-1.42) 
*follow up length reported for cohort studies only 
Definition of advanced prostate cancer: a Gleason ≥7; b ≥stage 3b, N1, M1 or fatal prostate cancer; c ≥stage 2; d 
≥stage 3 or fatal prostate cancer with unknown stage at diagnosis; e high stage (not defined); f Gleason ≥8 or 
regional/distant stage; g ≥stage 3; h ≥stage 3, N1, M1; i Gleason ≥4+3; j Gleason ≥8 
HR=hazard ratio; NR=not reported; OR=odds ratio; RR=relative risk ratio
  
